PharmOptimist schreef op 1 oktober 2017 20:44:
Kan iemand van het forum die er verstand van heeft kijken of dit klopt?
Sharon Curtiss Comment I posted Sept 28th.
Ruconest is for acute attacks ONLY, not prevention, and it has not been tested against the full spectrum of the disease, meaning it may not be effective for Type I. Cinryze and Haegardia are the preventive treatments and have been tested against all types. Cinryze of course is IV and Haegardia is subQ only. SubQ is the direction the research is going. Shire has two products on deck in Phase 3 trials, a C1-INH, liquid subQ and a monoclonal antibody injection both tested against the full spectrum, and these are administered much less frequently. The results make them excellent options of even replacements for Cinzryze. Ruconest might be used as an alternative to Firazyr, which is also an acute treatment. My dnl is one of the worst cases of Type I and Cinzyrze has been a miracle. Without she has had more attacks than before treatment and the medium that carriers the active ingredient in Firazyr is very painful. Something as to give here very soon because the attacks are becoming more frequent and the injection makes her tired. She can't do anything in this state.